Journal: Cell reports
Article Title: MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer.
doi: 10.1016/j.celrep.2025.115722
Figure Lengend Snippet: Figure 3. Cell-cycle arrest and apoptosis induced by the combination treatment (A and B) Flow cytometry analysis of EdU (5-ethynyl-2’-deoxyuridine) and DNA staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 48 h, then incubated with EdU for 2 h and stained for EdU and FxCycle Violet. Representative flow cytometry dot plots illustrating the gating strategy (A). A, G0/G1; B, S; C, G2/M. Percentages of cells in G0/G1, S, or G2/M phase are presented as mean ± SD (B). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated using one-way ANOVA followed by Tukey’s multiple comparisons test. n = 3 biological replicates. (C) Flow cytometry analysis of phosphatidylinositol (PI) and Annexin V staining. H460 and H1703 cells were treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 72 h. Representative flow cytometry dot plots illustrating the gating strategy. A, necrotic; B, late apoptotic; C, early apoptotic. (D) Percentages of cells in necrotic, late-apoptotic, or early-apoptotic status treated with vehicle, MYCi975 (5 μM), TMP195 (25 μM), or both for 24, 48, and 72 h are presented as mean ± SD. n = 3 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 calculated for necrotic + apoptotic cell percentages for each condition using one-way ANOVA followed by Tukey’s multiple comparisons test. V, vehicle; M, MYCi975; T, TMP195; C, combo (B and D).
Article Snippet: Cell viability assay with MYC overexpressing H460 cells pcDNA3-cMYC (Addgene, #16011) was reverse-transfected in H460 cells using Lipofectamine 3000 Transfection Reagent (Invitrogen, #L3000001) following the manufacturer’s protocol.
Techniques: Flow Cytometry, Staining, Incubation
Addgene inc is a verified supplier 
